TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02419183

Intervention type: OTHER
Intervention: SAMSTAR
Description: This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.

Intervention type: OTHER
Intervention: RAVLT
Description: This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
Study: NCT01407822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
Study: NCT02419183

Intervention type: OTHER
Intervention: RAVLT
Description: This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
Study: NCT02669004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bolus epidural morphine
Description: morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural morphine
Description: morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
Study: NCT00784615

Intervention type: PROCEDURE
Intervention: Blood samples, transvaginal ultrasound
Description: Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein

Intervention type: PROCEDURE
Intervention: Blood samples, transvaginal ultrasound
Description: Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
Study: NCT00138034

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI with bare metal stent placement of the culprit lesion the in the infarct related artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
Study: NCT01986569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoroestradiol (FES)
Description: \[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
Study: NCT03705962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: normal saline
Study: NCT01996137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VASST II treadmill
Description: Supervised treadmill training under physiotherapist
Study: NCT01407822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/cisplatin
Description: In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
Study: NCT01331122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: droxidopa
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
Study: NCT04548687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide insufflation
Description: Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No carbon dioxide insufflation
Description: standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
Study: NCT03422406

Intervention type: OTHER
Intervention: Dietary iodine intake restriction
Description: All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.

Intervention type: OTHER
Intervention: Dietary iodine intake restriction
Description: All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
Study: NCT00908206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809
Description: Subjects will receive a single 175 mg oral dose of GSK598809.
Study: NCT01331122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: droxidopa
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
Study: NCT03354078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interrupted sutures
Description: The way of closing subcutaneous tissue either by interrupted

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interrupted sutures
Description: The way of closing subcutaneous tissue either by interrupted

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continous sutures
Description: The way of closure of subcutanous tissue is by continous sutures
Study: NCT03352414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: alvimopan pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study: NCT04758273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage
Study: NCT03354078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continous sutures
Description: The way of closure of subcutanous tissue is by continous sutures
Study: NCT04758273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage
Study: NCT03890406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium: PTC(Post-tetanic count) 1~2
Description: Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium: TOF(Train-of-four) 1~2
Description: Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Study: NCT01816529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride 2% Cream
Description: 0.2 g applied topically to the infrascapular area of the back.
Study: NCT04758273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01816529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Study: NCT04758273

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02028429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil.
Description: Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
Study: NCT03943758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prepackaged Low-residue diet
Description: Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Self-prepared Low-residue diet
Description: Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
Study: NCT01816529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% solution of sodium lauryl sulfate (SLS)
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9%)
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Study: NCT02253706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen supplementation
Description: High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low flow nasal oxygen supplementation
Description: Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
Study: NCT03367130

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone reminder
Description: Intervention described already in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone reminder
Description: Intervention described already in arm/group descriptions.
Study: NCT01165723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
Study: NCT06490159

Intervention type: DRUG
Intervention: Paclitaxel
Description: Gastric cancer second-line chemotherapy

Intervention type: DRUG
Intervention: Paclitaxel
Description: Gastric cancer second-line chemotherapy
Study: NCT00781261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive a placebo drug for a similar period
Study: NCT03787615

Intervention type: DEVICE
Group type: OTHER
Intervention: sipIT tools
Description: Just in time drinking detection tools to promote increase fluid consumption
Study: NCT00493779

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Blood Collection
Description: 4 weeks
Study: NCT00895037

Intervention type: DRUG
Intervention: ReFacto AF (Moroctocog alfa)
Description: Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
Study: NCT01383850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP + standard air
Description: NCAP (SiPAP, Vyasis) was used to administer standard air

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP + standard air
Description: NCAP (SiPAP, Vyasis) was used to administer standard air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP + Heliox
Description: Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP + Heliox
Description: Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
Study: NCT02630290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine
Description: Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
Study: NCT00351351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberwand
Description: FDA approved - dual probe intracorporeal lithotrite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single probe ultrasonic
Description: FDA-approved - single probe ultrasonic
Study: NCT04063319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Description: The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
Study: NCT01010815

Intervention type: PROCEDURE
Intervention: Colonoscopy biopsy
Description: Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry

Intervention type: OTHER
Intervention: stool collection
Description: Stool will be collected from participants at study entry

Intervention type: PROCEDURE
Intervention: colonoscopy biopsy
Description: colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase

Intervention type: OTHER
Intervention: stool collection
Description: stool will be collected from participants 2 times during study - at active phase and inactive phase
Study: NCT02116894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
Study: NCT00668447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Isolate
Description: 20 grams of powder mixed in beverages or food daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Isolate
Description: 20 grams of powder mixed in beverages or food daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control protein
Description: 20 grams of powder mixed in beverages or food daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control protein
Description: 20 grams of powder mixed in beverages or food daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novasoy isoflavones
Description: 3 tablets daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novasoy isoflavones
Description: 3 tablets daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: 3 tablets daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: 3 tablets daily for one year
Study: NCT03608306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer
Description: enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk-fill glass hybrid restorative
Description: It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
Study: NCT02981316

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX7455
Description: Microbiota capsule(s) given twice daily in the morning, and in the evening.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX7455
Description: Microbiota capsule(s) given twice daily in the morning, and in the evening.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX7455
Description: Microbiota capsule(s) given twice daily in the morning, and in the evening.
Study: NCT03940924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: High Intensity Interval Training + Resistance Training (HIIT + RT)
Study: NCT02036593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk Your Heart to Health
Description: Walking group sessions conducted 3 times per week for 32 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Walk Your Heart to Health
Description: Walking group sessions conducted 3 times per week for 32 weeks.
Study: NCT01005719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid
Description: Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
Study: NCT01368341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 1 tablet, 100 mg, b.i.d. 14 days
Study: NCT02981316

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX7455
Description: Microbiota capsule(s) given twice daily in the morning, and in the evening.
Study: NCT01567241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical hypnosis or relaxation music
Description: 25 minute tape recording

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clinical hypnosis or relaxation music
Description: 25 minute tape recording
Study: NCT02105155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion at day 7 ± 3 Prograf® to Advagraf®
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conversion at day 90±5 Prograf® to Advagraf®
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
Study: NCT03020719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Glutathione
Description: Oral Glutathione oral powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral powder
Study: NCT03492658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.